New cancer drug LB4330 tested in early trial
NCT ID NCT05707676
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase trial tested a new drug called LB4330 in people with advanced solid tumors that had stopped responding to standard treatments. LB4330 is designed to help the immune system attack cancer cells. The study aimed to find a safe dose and check for side effects, but it was terminated early.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LB4330 (a fusion protein that targets Claudin 18.2 on tumor cells and activates CD8 T cells)
- What this could lead to
- If successful, this could point toward a new treatment option for advanced solid tumors like stomach or pancreatic cancer.
- What could go wrong
- This is a very early (Phase 1) trial that was terminated, so results are limited. The drug may not be effective or safe in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200120, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can your own immune cells beat advanced cancer?
- Can a Tumor's DNA guide better cancer care for kids?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a new PET tracer reveal a key cancer target?